YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Wins and Deals at JP Morgan


January 13, 2014 | Luke Timmerman has a good roundup of the buzz and trends at the JP Morgan Healthcare Conference. The conference is still ongoing, but the winners so far appear to be Intercept Pharmaceuticals, a small New York company with a liver damage drug so successful that trials were stopped early; immuno-oncology as a field; rare diseases as targets; and Alnylam. Alnylam signed a deal with Genzyme to the tune of $700 million, and immediately used some of its new cash flow to buy RNAi technologies and Sirna Therapeutics from Merck. Xconomy
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.